KZIA — Kazia Therapeutics Share Price
Last trade - 00:00- $11.97m
- $9.67m
- AU$0.02m
- 14
- 10
- 72
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.76 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 407.41 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -101.06% | ||
| Return on Equity | -134.97% | ||
| Operating Margin | -91918.57% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.1 | 0.07 | 15.22 | 0 | 0.02 | 0.09 | 0.81 | -28.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- June 30th, 2023
- Incorporated
- March 18th, 1994
- Public Since
- September 1st, 1994
- No. of Shareholders
- 3,204
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 228,029,114
- Address
- Three International Towers Level 24, SYDNEY, 2000
- Web
- https://www.kaziatherapeutics.com/
- Phone
- +61 294724100
- Auditors
- BDO Australia Ltd
Upcoming Events for KZIA
Similar to KZIA
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 21:34 UTC, shares in Kazia Therapeutics are trading at $0.27. This share price information is delayed by 15 minutes.
Shares in Kazia Therapeutics last closed at $0.27 and the price had moved by -78.24% over the past 365 days. In terms of relative price strength the Kazia Therapeutics share price has underperformed the S&P500 Index by -82.69% over the past year.
The overall consensus recommendation for Kazia Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Kazia Therapeutics does not currently pay a dividend.
Kazia Therapeutics does not currently pay a dividend.
Kazia Therapeutics does not currently pay a dividend.
To buy shares in Kazia Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.27, shares in Kazia Therapeutics had a market capitalisation of $6.10m.
Here are the trading details for Kazia Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: KZIA
Based on an overall assessment of its quality, value and momentum Kazia Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Kazia Therapeutics is $2.04. That is 661.65% above the last closing price of $0.27.
Analysts covering Kazia Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.06 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kazia Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -42.86%.
As of the last closing price of $0.27, shares in Kazia Therapeutics were trading -42.17% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kazia Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Kazia Therapeutics' directors